Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Mineralys Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

 LATE-BREAKING PRESENTATION OF EXPLORE-CKD TRIAL AT ASN KIDNEY WEEK   PIVOTAL PHASE 3 LAUNCH-HTN TRIAL FEATURED IN THE BEST OF JAMA AND NEJM SESSION - RADNOR, PA., NOV. 07, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING THERAPIES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT CLINICAL DATA FOR LORUNDROSTAT WERE PRESENTED AT THE AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025.

DATA FOR LORUNDROSTAT IN CHRONIC KIDNEY DISEASE AND HYPERTENSION PRESENTED AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025

~ LATE-BREAKING PHASE 2 TRIAL DATA EVALUATING THE SAFETY AND EFFICACY OF 25 MG OF LORUNDROSTAT IN PARTICIPANTS WITH HYPERTENSION AND COMORBID CKD TO BE PRESENTED~ ~ PHASE 3 DATA OF THE LAUNCH-HTN TRIAL OF LORUNDROSTAT TO BE INCLUDED IN BEST OF JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION AND THE NEW ENGLAND JOURNAL OF MEDICINE PRESENTATION~ RADNOR, PA., OCT. 21, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT DATA FROM THE PHASE 2 EXPLORE-CKD TRIAL EVALUATING THE SAFETY AND EFFICACY OF 25 MG OF LORUNDROSTAT IN PARTICIPANTS WITH HYPERTENSION AND COMORBID CKD WILL BE PRESENTED IN A LATE-BREAKING CLINICAL TRIALS SESSION AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025, BEING HELD NOVEMBER 6 -9 IN HOUSTON, TEXAS.

MINERALYS THERAPEUTICS ANNOUNCES LATE-BREAKING PRESENTATION OF PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT AT AMERICAN SOCIETY OF NEPHROLOGY (ASN) KIDNEY WEEK 2025

~ TOPLINE RESULTS FROM THE EXPLORE-OSA TRIAL ARE ANTICIPATED IN 1Q 2026 ~ RADNOR, PA., SEPT. 30, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED THAT IT HAS COMPLETED ENROLLMENT IN ITS PHASE 2 EXPLORE-OSA TRIAL OF LORUNDROSTAT IN PARTICIPANTS WITH MODERATE-TO-SEVERE OSA AND HYPERTENSION.

MINERALYS THERAPEUTICS COMPLETES ENROLLMENT IN PHASE 2 EXPLORE-OSA TRIAL OF LORUNDROSTAT IN OBSTRUCTIVE SLEEP APNEA AND HYPERTENSION

~PIVOTAL LAUNCH-HTN TRIAL OF NOVEL ALDOSTERONE SYNTHASE INHIBITOR LORUNDROSTAT ENROLLED A DIVERSE RANGE OF PARTICIPANTS WITH UNCONTROLLED OR RESISTANT HYPERTENSION~

MINERALYS THERAPEUTICS PRESENTS SUBGROUP ANALYSES OF PHASE 3 LAUNCH-HTN TRIAL DEMONSTRATING EFFICACY AND SAFETY OF LORUNDROSTAT IN HYPERTENSION PARTICIPANTS WITH HIGH UNMET MEDICAL NEED

RADNOR, PA., SEPT. 04, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 11,274,509 SHARES OF ITS COMMON STOCK, WHICH INCLUDES THE EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE UP TO 1,470,588 ADDITIONAL SHARES OF ITS COMMON STOCK, AT A PUBLIC OFFERING PRICE OF $25.50 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO MINERALYS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, WERE APPROXIMATELY $287.5 MILLION. ALL OF THE SECURITIES SOLD IN THE OFFERING WERE SOLD BY MINERALYS.

MINERALYS THERAPEUTICS ANNOUNCES CLOSING OF UPSIZED $287.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK INCLUDING FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES

RADNOR, PA., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THE PRICING OF AN UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 9,803,921 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $25.50 PER SHARE. THE AGGREGATE GROSS PROCEEDS TO MINERALYS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $250.0 MILLION. IN ADDITION, MINERALYS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 1,470,588 SHARES OF ITS COMMON STOCK. ALL OF THE SECURITIES TO BE SOLD IN THE OFFERING ARE TO BE SOLD BY MINERALYS. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT SEPTEMBER 4, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

MINERALYS THERAPEUTICS ANNOUNCES PRICING OF UPSIZED $250.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

RADNOR, PA., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS CHRONIC KIDNEY DISEASE (CKD), OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, ANNOUNCED TODAY THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF $175.0 MILLION OF SHARES OF ITS COMMON STOCK.

MINERALYS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

 PRESENTED AND PUBLISHED THE POSITIVE RESULTS FROM BOTH THE LAUNCH-HTN AND ADVANCE-HTN PIVOTAL TRIALS AT SCIENTIFIC MEETINGS AND IN JAMA AND NEJM   PRE-NDA MEETING SCHEDULED TO TAKE PLACE IN 4Q 2025   EXPLORE-CKD PHASE 2 TRIAL SUCCESSFULLY ACHIEVED STATISTICAL SIGNIFICANCE IN REDUCTION OF SYSTOLIC BP AND UACR, AND DEMONSTRATED A FAVORABLE SAFETY PROFILE   EXPLORE-OSA PHASE 2 TRIAL IN OSA PARTICIPANTS WITH HYPERTENSION IS ONGOING; TOPLINE RESULTS ANTICIPATED IN 1H 2026   CONFERENCE CALL TODAY AT 4:30 P.M. ET  RADNOR, PA.

MINERALYS THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

RADNOR, PA., AUG. 04, 2025 (GLOBE NEWSWIRE) -- MINERALYS THERAPEUTICS, INC. (NASDAQ: MLYS), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING MEDICINES TO TARGET HYPERTENSION AND RELATED COMORBIDITIES SUCH AS HYPERTENSIVE NEPHROPATHY, OBSTRUCTIVE SLEEP APNEA (OSA) AND OTHER DISEASES DRIVEN BY DYSREGULATED ALDOSTERONE, TODAY ANNOUNCED IT WILL REPORT ITS FINANCIAL RESULTS FROM THE SECOND QUARTER ENDED JUNE 30, 2025, AFTER THE FINANCIAL MARKETS CLOSE ON TUESDAY, AUGUST 12, 2025.

MINERALYS THERAPEUTICS TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTS AND HOST CONFERENCE CALL ON TUESDAY, AUGUST 12, 2025

 THE LAUNCH-HTN TRIAL IS THE LARGEST TRIAL OF AN ALDOSTERONE SYNTHASE INHIBITOR COMPLETED IN PARTICIPANTS WITH UNCONTROLLED OR TREATMENT RESISTANT HYPERTENSION 

MINERALYS THERAPEUTICS ANNOUNCES JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA) PUBLICATION OF PIVOTAL PHASE 3 LAUNCH-HTN TRIAL FOR LORUNDROSTAT

 EXPLORE-CKD MET ITS PRIMARY ENDPOINT; LORUNDROSTAT 25 MG ONCE DAILY ACHIEVED A 9.3 MMHG REDUCTION IN SYSTOLIC BLOOD PRESSURE, AND A 7.5 MMHG PLACEBO-ADJUSTED REDUCTION (P=0.0024) AT FOUR WEEKS   LORUNDROSTAT SHOWED A CLINICALLY MEANINGFUL REDUCTION IN THE PRE-DEFINED ENDPOINT SPOT URINE ALBUMIN-TO-CREATININE RATIO OF 31% (P6.0 MMOL/L) 0/59 (0%) 3/58 (5%)  BP, BLOOD PRESSURE; UACR, URINE ALBUMIN-TO-CREATININE RATIO; TEAE, TREATMENT-EMERGENT ADVERSE EVENT * PRIMARY ENDPOINT. ** CYSTATIN-C FORMULA, A SURROGATE BIOMARKER OF RENAL FUNCTION NOT SUBJECT TO MATE1 TRANSPORT AND ELIMINATION IN THE GLOMERULI OF THE KIDNEY.

MINERALYS THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 EXPLORE-CKD TRIAL OF LORUNDROSTAT FOR THE TREATMENT OF HYPERTENSION IN SUBJECTS WITH CKD AND ALBUMINURIA

Mineralys Therapeutics, Inc.

MLYS

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Mineralys Therapeutics, Inc.

MLYS.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MLYS